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Associations of Medicaid Expansion With Insurance Coverage, Stage at Diagnosis,
and Treatment Among Patients With Genitourinary Malignant Neoplasms
Katharine F. Michel, MD, MSHP; Aleigha Spaulding, MPH; Ahmedin Jemal, PhD, DVM; K. Robin Yabroff, PhD; Daniel J. Lee, MD, MS; Xuesong Han, PhD

Abstract

Key Points

IMPORTANCE Health insurance coverage is associated with improved outcomes in patients with
cancer. However, it is unknown whether Medicaid expansion through the Patient Protection and
Affordable Care Act (ACA) was associated with improvements in the diagnosis and treatment of
patients with genitourinary cancer.

Question Is the Patient Protection and
Affordable Care Act’s Medicaid
expansion associated with the
presentation and management of
genitourinary cancers?

OBJECTIVE To assess the association of Medicaid expansion with health insurance status, stage at

Findings In this case-control study

diagnosis, and receipt of treatment among nonelderly patients with newly diagnosed kidney,

including 340 552 patients with newly

bladder, or prostate cancer.

diagnosed genitourinary cancer in the
National Cancer Database from 2011 to

DESIGN, SETTING, AND PARTICIPANTS This case-control study included adults aged 18 to 64

2016, a difference-in-difference analysis

years with a new primary diagnosis of kidney, bladder, or prostate cancer, selected from the National

found that, compared with states that

Cancer Database from January 1, 2011, to December 31, 2016. Patients in states that expanded

did not expand Medicaid, Medicaid

Medicaid were the case group, and patients in nonexpansion states were the control group. Data

expansion was significantly associated

were analyzed from January 2020 to March 2021.

with a decreased uninsured rate, an
increased proportion of early-stage
diagnosis for kidney and prostate

EXPOSURES State Medicaid expansion status.

cancers, and an increased proportion of

MAIN OUTCOMES AND MEASURES Insurance status, stage at diagnosis, and receipt of cancer and

patients receiving active surveillance

stage-specific treatments. Cases and controls were compared with difference-in-difference analyses.

for low-risk prostate cancer, with larger
magnitudes of association observed in

RESULTS Among a total of 340 552 patients with newly diagnosed genitourinary cancers, 94 033
(27.6%) had kidney cancer, 25 770 (7.6%) had bladder cancer, and 220 749 (64.8%) had prostate
cancer. Medicaid expansion was associated with a net decrease in uninsured rate of 1.1 (95% CI, −1.4
to −0.8) percentage points across all incomes and a net decrease in the low-income population of 4.4
(95% CI, −5.7 to −3.0) percentage points compared with nonexpansion states. Expansion was also
associated with a significant shift toward early-stage diagnosis in kidney cancer across all income
levels (difference-in-difference, 1.4 [95% CI, 0.1 to 2.6] percentage points) and among individuals
with low income (difference-in-difference, 4.6 [95% CI, 0.3 to 9.0] percentage points) and in

the low-income population.
Meaning These findings suggest that
Medicaid expansion was associated with
downstream diagnosis and treatment
outcomes for genitourinary malignant
neoplasms and may reduce
socioeconomic disparities in
these metrics.

prostate cancer among individuals with low income (difference-in-difference, 3.0 [95% CI, 0.3 to 5.7]
percentage points). Additionally, there was a net increase associated with expansion compared with
nonexpansion in receipt of active surveillance for low-risk prostate cancer of 4.1 (95% CI, 2.9 to 5.3)
percentage points across incomes and 4.5 (95% CI, 0 to 9.0) percentage points among patients in lowincome areas.

+ Supplemental content
Author affiliations and article information are
listed at the end of this article.

CONCLUSIONS AND RELEVANCE These findings suggest that Medicaid expansion was associated
with decreases in uninsured status, increases in the proportion of kidney and prostate cancer
diagnosed in an early stage, and higher rates of active surveillance in the appropriate, low-risk
(continued)
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Abstract (continued)

prostate cancer population. Associations were concentrated in population residing in low-income
areas and reinforce the importance of improving access to care to all patients with cancer.
JAMA Network Open. 2021;4(5):e217051. doi:10.1001/jamanetworkopen.2021.7051

Introduction
One of the major components of the 2010 Patient Protection and Affordable Care Act (ACA) was the
expansion of Medicaid coverage eligibility to 138% of the federal poverty level (FPL). While this
expansion was intended to decrease rates of the individuals who are uninsured across the entire US
population, in 2012, the Supreme Court made this expansion optional for states.1 In January 2014, 25
states and the District of Columbia opted to expand Medicaid, and several more states expanded in
the ensuing years.2 This staggered and incomplete expansion pattern provides a natural experiment
to study the association of the Medicaid expansion with population health.
The association of the Medicaid expansion with the detection and management of
genitourinary malignant neoplasms is particularly important, since some of these cancers are among
the most commonly diagnosed and costliest in the US. Prostate cancer is the most common cancer
in men, and across sexes, bladder cancer is the sixth most common and kidney cancer is the eighth
most common. Prostate, bladder, and kidney cancers collectively account for about 20% of newly
diagnosed cancer cases in the US each year (347 080 of 1.8 billion estimated new cancer diagnoses in
2020).3 Regarding costs, prostate cancer is the fifth most expensive cancer, while bladder cancer is
the ninth most expensive, and kidney cancer is the tenth most expensive, and these cancers
accounted for more than $26 billion in estimated spending in 2020.4 Within these discussions of
genitourinary cancer diagnosis and management, there are well-established racial/ethnic and
socioeconomic disparities5-10 that could be potentially alleviated by expanded insurance coverage
and access to care. Being uninsured is associated with higher odds of presenting with advanced stage
cancer,10-16 being undertreated,12-15 and having worse survival.10,12,14,15,17,18 Furthermore, positive
associations between health insurance coverage and outcomes are larger in magnitude for
low-income populations.19
Previous research on the associations of Medicaid expansion with cancer care has focused on
the association of expansion with the decreasing proportion of uninsured individuals rather than
other aspects of cancer care, such as diagnosis and treatment.20-23 Only a handful of studies have
studied further downstream metrics, and they have identified small shifts to earlier stage disease in
a few nongenitourinary cancers21,22,24 and an increase in utilization of surgery for all cancers in
aggregate.25-27 However, these studies have generally been limited to only a year of
postimplementation data, and the association of Medicaid expansion with alleviating racial/ethnic or
socioeconomic disparity has been inconsistent between different subgroups and cancer types.20
The objective of this study was to evaluate the association of Medicaid with the continuum of
genitourinary cancer care, including insurance status, stage at diagnosis, and receipt of specific
surgical and nonsurgical treatments, with a focus on patients residing in low-income areas.

Methods
This case-control study was granted exemption from review by the Morehouse School of Medicine
Institutional Review Board. Informed consent was waived because data were deidentified. This study
is reported following the Reporting of Studies Conducted Using Observational Routinely-Collected
Data (RECORD) reporting guidelines.
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Patient Population
Patients aged 18 to 64 years who were newly diagnosed with a first primary kidney, bladder, or
prostate cancer between January 1, 2011, and December 31, 2016, were identified from the National
Cancer Database (NCDB), a hospital-based cancer registry cosponsored by the American College of
Surgeons and the American Cancer Society. The NCDB collects cancer diagnoses from all Commission
on Cancer–accredited hospitals annually, capturing approximately 72% of all US cancer cases,
including 78% of kidney cancers, 70% of bladder cancers, and 58% of prostate cancers.28-30
We excluded the 3 months before and after Medicaid expansion for expansion states and
October 2013 through March 2014 for nonexpansion states to create a phase-in or wash-out period.21
We identified our sample by selecting primary site codes for kidney (C64), bladder (C670-C676,
C678, or C679), and adenocarcinoma of the prostate (C619, histology code 8140) according to the
International Classification of Disease for Oncology, Third edition,31 topography codes. For
treatment-related outcomes, additional inclusion and exclusion criteria are detailed in eTable 1 in the
Supplement. For treatment outcomes, patients diagnosed in the second half of 2016 were excluded
for possible reporting lag.

Outcomes and Covariates
Our outcomes were insurance status at the time of diagnosis (uninsured, Medicaid, private, or other),
proportion of early-stage diagnosis (American Joint Committee on Cancer stage 1 for kidney cancer,
American Joint Committee on Cancer stage 0-1 for bladder cancer, and National Comprehensive
Cancer Network very low– or low-risk groups for prostate cancer), and a selection of cancer- and
stage-specific treatment outcomes. Receipt of the first course of treatment, such as surgery,
radiation, hormone therapy, and chemotherapy, including active surveillance or watchful waiting for
prostate cancer, is reported in the NCDB.32
Demographic variables captured and categorized in the NCDB were age group at diagnosis
(18-44, 45-54, or 55-64 years), sex (male or female), race/ethnicity (non-Hispanic White,
non-Hispanic Black, non-Hispanic other, Hispanic, or unknown), zip code–level median income
(<139% FPL, 139%-400% FPL, or >400% FPL), metropolitan statistical area (metropolitan, urban,
rural, or unknown), Charlson-Deyo comorbidity score (0, 1, or ⱖ2), and facility case volume (disease
specific and by quartile). The NCDB data are collected by electronic medical record review by trained
abstractors. Race/ethnicity reflects is recorded in the patient’s medical record; however each
participating institution may document race/ethnicity in the medical record by different means, and
these means are not recorded by the NCDB.

Statistical Analysis
We used χ2 tests to compare overall distribution of demographic variables between patients residing
in expansion vs nonexpansion states. As a standard statistical approach for evaluating the association
of health policy changes in quasi-experimental studies, difference-in-difference method was
employed, which involves generating a linear probability regression for each outcome that contains
binary variables indicating before or after and exposure or control, as well as an interaction
variable.33,34 This interaction term describes the percentage point change associated with the
exposure from before the exposure to after, while controlling for contemporaneous before to after
changes in the control group. Our case group included patients in states that expanded Medicaid, and
the control group included patients in states that did not expand Medicaid. The before and after
periods were usually defined as 2010 to 2013 for pre-ACA Medicaid expansion and 2014 to 2016 for
post-ACA Medicaid expansion. However, states that expanded Medicaid after January 2014 (ie,
Michigan expanded Medicaid on April 1, 2014; New Hampshire, August 15, 2014; Pennsylvania,
January 1, 2015; Indiana, February 1, 2015; Alaska, September 1, 2015; Montana, January 1, 2016; and
Louisiana, July 1, 2016), were defined based on the actual expansion date. Absolute percentages of
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each of our outcomes were observed graphically over the entire study period, and the difference-indifference parallel trends assumption was evaluated using 2013 as a placebo year of policy change
for patients diagnosed before 2014 (eTable 2 in the Supplement).
We generated crude and adjusted difference-in-difference models controlling for age, sex, race/
ethnicity, zip code–level income, and metropolitan statistical area status. We accounted for secular
trends by including a continuous form of diagnosis year in the model, and accounted for clustering at
the state level by using random effects modeling,35 as used in previous studies on Medicaid
expansion and health care outcomes.36,37 The model equation is:
Yist = β1expansions + β2postt + β3expansions × postt + ΣγkXik + δs + ηt + εist, in which i indicates the
individual patient; s, the state; and t, the year. The expansion and post variables indicate yes/no
Medicaid expansion status and post-ACA expansion status. Xik indicates the k characteristic covariate
controlled; δs, random effects for each state; and ηt, the linear time trend. β3 in the regression
specification is the difference-in-difference estimator for changes in outcome Y associated with
Medicaid expansion after implementation of the ACA.
Charlson-Deyo comorbidity score and facility case volume were added to multivariable
difference-in-difference models for treatment outcomes. Missing values were treated as a separate
unknown category in the models. In addition to overall sample, we also conducted subset analyses
stratifying by cancer type and limiting to patients living in low-income areas. To assess the robustness
of difference-in-difference estimates to unmeasured confounders, we calculated the E values which
represent the minimum strength of association that would be required between an unmeasured
confounder and both state’s Medicaid expansion status and changes in disease outcomes to
overcome the statistically significant outcome observed.38
All P values were 2-sided and deemed statistically significant at α = .05. All statistical analyses
were conducted using SAS statistical software version 9.4 (SAS Institute). Data were analyzed from
January 2020 to March 2021.

Results
A total of 340 552 new diagnoses genitourinary cancers were identified in the NCDB in patients aged
18 to 64 years between 2011 to 2016, including 94 033 patients (27.6%) with kidney cancer, 25 770
patients (7.6%) with bladder cancer, and 220 749 patients (64.8%) with prostate cancer. Among
these, 210 570 patients (61.8%) were in expansion states, and 129 982 patients (38.2%) were in
nonexpansion states. Black and low-income patients were disproportionately represented in
nonexpansion states (Table 1).

Changes in Insurance Status
Medicaid expansion was associated with a net increase of 4.5 (95% CI, 4.2 to 4.9) percentage points
in the proportion of patients with Medicaid insurance, a net decrease of 3.1 (95% CI, −3.6 to −2.5)
percentage points in patients with private insurance, and a net decrease of 1.1 (95% CI, −1.4 to −0.8)
percentage points in patients who were uninsured. These net changes were even larger in the
low-income population, with an increase of 9.8 (95% CI, 8.0 to 11.6) percentage points in patients
enrolled in Medicaid, a decrease of 3.6 (95% CI, −6.1 to −1.2) percentages in patients with private
insurance, and a decrease of 4.4 (95% CI, −5.7 to −3.0) in patients who were uninsured (eTable 3 in
the Supplement). In expansion states, there was a decrease in the proportion of patients who were
uninsured (absolute percentage change [APC], −2.3 [95% CI, −2.5 to −2.2] percentage points), driven
mainly by a proportional increase in Medicaid insurance (APC, 5.0 [95% CI, 4.8 to 5.3] percentage
points). By contrast, the decrease in patients who were uninsured in nonexpansion states (APC, −1.2
[95% CI, −1.4 to −0.9] percentage points) was smaller and wholly associated with an increase in
privately insured patients (APC, 0.5 [95% CI, 0.0 to 1.0] percentage points) rather than Medicaid.
The eFigure and eTable 4 in the Supplement show the data biannually to better describe
these trends.
JAMA Network Open. 2021;4(5):e217051. doi:10.1001/jamanetworkopen.2021.7051 (Reprinted)
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Table 1. Characteristics of Patients Newly Diagnosed With Genitourinary Malignant Neoplasms
in the National Cancer Database from 2011 to 2016
No. (%)a

Variable

Total
(n = 340 552)

Expansion states (n = 210 570)

Nonexpansion states (n = 129 982)

Pre-ACA

Post-ACA

Pre-ACA

Post-ACA
19 312 (31.2)

Primary neoplasm site
Kidney

94 033 (27.6)

29 835 (25)

26 837 (29.3)

18 049 (26.5)

Bladder

25 770 (7.6)

9043 (7.6)

7408 (8.1)

4686 (6.9)

4633 (7.5)

Prostate

220 749 (64.8)

80 247 (67.4)

57 200 (62.6)

45 432 (66.6)

37 870 (61.3)

2011

70 574 (20.7)

43 681 (36.7)

0

26 893 (39.5)

0

2012

61 995 (18.2)

38 319 (32.2)

0

23 676 (34.7)

0

2013

47 985 (14.1)

30 387 (25.5)

0

17 598 (25.8)

0

2014

43951 (12.9)

5096 (4.3)

22 024 (24.1)

0

16 831 (27.2)

2015

58 855 (17.3)

1372 (1.2)

34 246 (37.4)

0

23 237 (37.6)

2016

57 192 (16.8)

270 (0.2)

35 175 (38.5)

0

21 747 (35.2)

18-44

19 833 (5.8)

6372 (5.3)

5354 (5.9)

4084 (6)

4023 (6.5)

45-54

81 994 (24.1)

29 274 (24.6)

20 715 (22.7)

17 336 (25.4)

14 669 (23.7)

55-64

238 725 (70.1)

83 479 (70.1)

65 376 (71.5)

46 747 (68.6)

43 123 (69.8)

Non-Hispanic White

246 008 (72.2)

89 283 (74.9)

66 912 (73.2)

47 832 (70.2)

41 981 (67.9)

Non-Hispanic Black

59 751 (17.5)

17 766 (14.9)

13 142 (14.4)

14 718 (21.6)

14 125 (22.9)

Hispanic

21 205 (6.2)

6586 (5.5)

6550 (7.2)

4042 (5.9)

4027 (6.5)

Non-Hispanic other

9843 (2.9)

3862 (3.2)

3604 (3.9)

1160 (1.7)

1217 (2)

Unknown

3745 (1.1)

1628 (1.4)

1237 (1.4)

415 (0.6)

465 (0.8)

Men

301 118 (88.4)

106 540 (89.4)

80 558 (88.1)

60 267 (88.4)

53 753 (87)

Women

39 434 (11.6)

12 585 (10.6)

10 887 (11.9)

7900 (11.6)

8062 (13)

0

274 720 (80.7)

97 388 (81.8)

73 932 (80.8)

54 424 (79.8)

48 976 (79.2)

1

50 688 (14.9)

17 459 (14.7)

12 782 (14)

11 013 (16.2)

9434 (15.3)

≥2

15 144 (4.4)

4278 (3.6)

4731 (5.2)

2730 (4)

3405 (5.5)

Low (<139%)

25 915 (7.6)

7889 (6.6)

5566 (6.1)

6608 (9.7)

5852 (9.5)

Middle (139%-400%)

281 535 (82.7)

97 186 (81.6)

74 465 (81.4)

57 541 (84.4)

52 343 (84.7)

High (>400%)

32 315 (9.5)

13 703 (11.5)

11 217 (12.3)

3870 (5.7)

3525 (5.7)

Unknown

787 (0.2)

347 (0.3)

197 (0.2)

148 (0.2)

95 (0.2)

Diagnosis year

Age, y

Race/ethnicity

Sex

Comorbidity score

Income, FPL
Abbreviations: ACA, Patient Protection and Affordable
Care Act; FPL, federal poverty line; NCI, National
Cancer Institute.
a

Patients diagnosed 3 months before or 3 months
after Medicaid expansion in expansion states and
patients diagnosed in October 2013 to March 2014 in
nonexpansion states were excluded. Missing or
unknown values not shown in table.

b

Other facility type included Integrated Network
Cancer Program, Hospital Associate Cancer Program,
Pediatric Cancer Program, Free Standing Cancer
Center Program.

c

Facility volumes were calculated as the number of
patients treated in the facility in a year and
categorized based on quartiles: very low indicates 1
to 3 kidney cancer cases, 1 bladder cancer case, or 1 to
6 prostate cancer cases; low, 4 to 7 kidney cancer
cases, 2 bladder cancer cases, or 7 to 16 prostate
cancer cases; medium, 8 to 16 kidney cancer cases, 3
to 4 bladder cancer cases, or 7 to 16 prostate cancers;
high, 17 or more kidney cancer cases, 5 or more
bladder cancer cases, or 38 or more prostate
cancer cases.

Residence
Metropolitian

279 050 (81.9)

99 930 (83.9)

76 994 (84.2)

53 527 (78.5)

48 599 (78.6)

Urban

47 006 (13.8)

14 622 (12.3)

10 898 (11.9)

11 341 (16.6)

10 145 (16.4)

Rural

5987 (1.8)

1502 (1.3)

1147 (1.3)

1773 (2.6)

1565 (2.5)

Unknown

8509 (2.5)

3071 (2.6)

2406 (2.6)

1526 (2.2)

1506 (2.4)

Community

21 197 (6.2)

7225 (6.1)

5797 (6.3)

4016 (5.9)

4159 (6.7)

Comprehensive
community

121 490 (35.7)

37 801 (31.7)

29 059 (31.8)

28 636 (42)

25 994 (42.1)

Teaching or research

86 047 (25.3)

33 797 (28.4)

25 722 (28.1)

13 317 (19.5)

13 211 (21.4)

Facility type

NCI

60 491 (17.8)

22 271 (18.7)

19 139 (20.9)

9853 (14.5)

9228 (14.9)

Otherb

51 327 (15.1)

18 031 (15.1)

11 728 (12.8)

12 345 (18.1)

9223 (14.9)

Very Low

11 311 (3.3)

4142 (3.5)

3234 (3.5)

2084 (3.1)

1851 (3)

Low

31 474 (9.2)

11 562 (9.7)

9270 (10.1)

5111 (7.5)

5531 (8.9)

Medium

70 925 (20.8)

24 285 (20.4)

19 461 (21.3)

14 048 (20.6)

13 131 (21.2)

High

22 6842 (66.6)

79 136 (66.4)

59 480 (65)

46 924 (68.8)

41 302 (66.8)

Facility volumec
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Changes in Cancer Stage
Medicaid expansion was associated with a net increase of 1.4 (95% CI, 0.1 to 2.6) percentage points
in the proportion of kidney cancers diagnosed at stage 1 (Table 2). For the low-income group, the net
increase was 4.6 (95% CI, 0.3 to 9.0) percentage points.
In prostate cancer, there was a steady decline in the proportion of diagnoses made at early stage
in expansion (APC, −5.7 [95% CI, −6.2 to −5.3] percentage points) and nonexpansion (APC, −5.9
[95% CI, −6.5 to −5.3] percentage points) states (Table 2). In 2014, the decline did not change course
in nonexpansion states but plateaued slightly in expansion states (Figure 1; eTable 5 in the
Supplement), with a smaller magnitude decrease for expansion states. This is particularly true in the
low-income population, in which the APC was −6.2 (95% CI, −8.1 to −4.3) percentage points for
nonexpansion states and −3.3 (95% CI, −5.2 to −1.5) percentage points for expansion states. In the
adjusted model, the difference-in-difference estimate was a net increase of 3.0 (95% CI, 0.3 to 5.7)
percentage points in early-stage diagnoses associated with expansion.

Changes in Treatment
Table 3 shows the results from the difference-in-difference analyses to detect associations between
Medicaid expansion and changes in treatment. For kidney cancer, APCs show the proportion of stage
0 to 3 cancers receiving resection decreased, coupled with increase in use of biopsy and active
surveillance in expansion and nonexpansion states. The percentage of patients receiving biopsy had
the largest magnitude of increase, with an increase of 6.5 (95% CI, 4.9 to 8.1) percentage points in
expansion states and 4.8 (95% CI, 3.1 to 6.5) percentage points in nonexpansion states. In adjusted
models, the difference-in-difference estimator was a net increase of 1.5 (95% CI, −0.8 to 3.8)
percentage points in expansion states compared with nonexpansion states, but this result was no
longer statistically significant.
In bladder cancer, the proportions of early-stage cancers receiving resection were high and
unassociated with Medicaid expansion. By contrast, the proportion of patients receiving radical
cystectomy for muscle invasive bladder cancer was low, and the proportion of patients who then also
received the indicated neoadjuvant chemotherapy was even lower (Table 3). While the proportion
of patients receiving neoadjuvant chemotherapy increased in expansion (APC, 6.4 [95% CI, 2.1 to
10.7] percentage points) and nonexpansion states (APC, 11.4 [95% CI, 6.1 to 16.7]), there was no
statistically significant net change associated with Medicaid expansion.
For prostate cancer, the percentages of treatment for National Comprehensive Cancer Network
intermediate- and high-risk localized disease decreased from before to after expansion time periods
in expansion (APC, −2.6 [95% CI, −3.0 to −2.1] percentage points) and nonexpansion states (APC,
−2.0 [95% CI, −2.5 to −1.4] percentage points), and there was no net difference associated with
Medicaid expansion. The proportion of patients with low-risk disease who underwent active
surveillance increased throughout the study in expansion (APC, 13.5 [95% CI, 12.6 to 14.3]
percentage points) and nonexpansion (APC, 8.6 [95% CI, 7.7 to 9.6] percentage points) states
(Figure 2; eTable 6 in the Supplement). In the adjusted model, there was a net increase of 4.1 (95%
CI, 2.9 to 5.3) percentage points associated with Medicaid expansion across incomes and a net
increase of 4.5 (95% CI, 0 to 9.0) percentage points among patients in low-income areas.
E values to estimate the robustness of the observed associations to unmeasured confounding
suggested extensive unmeasured confounding would be required to eliminate observed associations
between Medicaid expansion and changes in outcomes (eTable 7 in the Supplement). For example,
the observed association of Medicaid expansion and increased diagnosis at an early stage of kidney
cancer could be explained by an unmeasured confounder that was associated with Medicaid
expansion and changes in stage at diagnosis by a risk ratio of 3.4 each, above and beyond the
measured confounds, but weaker confounding could not do so (eTable 7 in the Supplement).

JAMA Network Open. 2021;4(5):e217051. doi:10.1001/jamanetworkopen.2021.7051 (Reprinted)

Downloaded From: https://jamanetwork.com/ on 04/17/2022

May 19, 2021

6/15

220 749

Prostate cancer low riskb

1883

16 351

Bladder cancer stage 0-1

Prostate cancer low riskb
1269 (24.8)

214 (37.2)

1333 (60.8)

25 259 (31.5)

4078 (45.1)

18 119 (60.7)

Pre-ACA

719 (21.4)

164 (38.4)

1154 (64.6)

14 724 (25.7)

3353 (45.3)

16 607 (61.9)

Post-ACA

−3.3 (−5.2 to −1.5)a

1.2 (−4.9 to 7.3)

3.9 (0.8 to 6.9)a

−5.7 (−6.2 to −5.3)a

0.2 (−1.4 to 1.7)

1.2 (0.3 to 2)a

APC (95% CI)

Downloaded From: https://jamanetwork.com/ on 04/17/2022
APC (95% CI)
1.5 (0.2 to 2.7)a
.03

.03

.28

.03

.73

.64

Low-risk group defined according to National Comprehensive Cancer Network guidelines for very low– or low- risk strata (Gleason score ⱕ6; clinical T ⱕT2a; prostate-specific antigen <10).

2.9 (0.2 to 5.5)a

4.8 (−3.9 to 13.6)

4.9 (0.5 to 9.3)a

0.1 (−0.6 to 0.9)

0.6 (−1.9 to 3.1)

P value

This 95% CI does not overlap with 0; P < .05.

−6.2 (−8.1 to −4.3)a

−3.6 (−9.9 to 2.7)

−1.0 (−4.2 to 2.1)

−5.9 (−6.5 to −5.3)a

−0.4 (−2.4 to 1.6)

Difference-indifference, % (95% CI)

b

752 (21.2)

143 (33.3)

1132 (60.1)

9526 (25.2)

1901 (41.0)

11 750 (60.8) −0.3 (−1.3 to 0.7)

Post-ACA

a

1190 (27.4)

167 (36.9)

1113 (61.2)

14 096 (31.0)

1943 (41.5)

11 037 (61.2)

Pre-ACA

Crude
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Table 2. Cancer Diagnosis at an Early Stage from the Pre-ACA and Post-ACA Periods by Medicaid Expansion Status
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Discussion
In this case-control study, we evaluated associations between Medicaid expansion and changes in
insurance, stage at diagnosis, and treatment in patients with newly diagnosed bladder, kidney, or
prostate cancers. Our findings are consistent with earlier studies describing Medicaid’s association
with reductions in uninsured status and shifts toward earlier-stage disease at diagnosis for
non-Hodgkin lymphoma and pancreatic, liver, and thyroid cancer.21,22 To our knowledge, our study is
the first to associate Medicaid expansion with a stage shift for kidney and prostate cancer and also
with an increase in active surveillance of low-risk prostate cancer.
One of the most important takeaways from our study is the greater magnitude of all detected
changes in the low-income subanalysis compared with the entire population. Genitourinary
malignant neoplasms display varying degrees of racial/ethnic, sex, and socioeconomic disparities not
only in cancer survival but throughout the diagnosis and treatment process. In some genitourinary
cancers, insurance has been shown to act as an association modifier for these variables,16,39,40
indicating it may be a powerful tool to reduce disparity in cancer care and, ultimately, outcomes. The
decrease in uninsured status associated with Medicaid expansion in our study was 1.1 percentage
points across all incomes, but 4.4 percentage points in the low-income group. This trend is consistent
with other studies that have shown that Medicaid expansion was associated with reduced
socioeconomic disparity in insurance rates.20-22 Importantly, our findings suggest that the
downstream stage and treatment outcomes were also magnified in the low-income population. The
fact that changes in the low-income population are associated with trends toward earlier diagnosis
and receipt of indicated treatment suggests that expansion of insurance may be a valid mechanism to
help reduce cancer disparity.
The association between gaining insurance and improved cancer outcomes is likely
multifactorial and variable between different cancer types. For prostate cancer, an association
between gaining insurance and undergoing prostate-specific antigen (PSA) screening could explain
the association our study identified between insurance and early-stage diagnosis. Complicating this
explanation is the fact that recent studies have reported that the practice of PSA screening has been
decreasing over the past decade,41-43 and that this decrease was associated with decreasing
incidence both overall42-45 and specifically incidence of early-stage cancers.43 Our findings agree
with this trend by showing that low-risk prostate cancer has decreased in both Medicaid expansion
and nonexpansion states; however, our data also suggest that the rate of decrease was slower in
Medicaid expansion states, yielding a net increase in early-stage disease associated with Medicaid
expansion. Furthermore, despite the US Preventive Services Task Force’s 2012 recommendation
against PSA screening and mixed results associated with screening in other nongenitourinary cancers
associated with the ACA,46 a 2018 study by Sammon et al47 showed that between 2012 and 2014,
there was an increase in self-reported rates of PSA screening associated with early expansion of

Figure 1. Trend of Low-Risk Diagnosis for Prostate Cancer in All-Income and Low-Income Populations
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Medicaid. In general, studies have shown that insurance status48,49 and physician access50 increase
rates of PSA screening. Thus, while our study does not attempt to identify PSA screening as a factor, it
does offer a potential explanation for how Medicaid expansion is associated with moderating an
ongoing decrease in early-stage prostate cancer detection.
Critically, our data show that this net shift to earlier stage prostate cancer diagnosis was
accompanied by an increase in active surveillance associated with Medicaid expansion. The dual
existence of early detection via PSA screening and active surveillance is essential in building a strong
approach to prostate cancer care. Modeling studies suggest that 23% to 42% of all prostate cancers
in the US detected in screening examinations were overtreated.51 PSA screening has been shown to
be associated with a 40% reduction in prostate cancer death,52 but PSA screening will continue to
be controversial without a reduction in overtreatment. It has been demonstrated that active
surveillance is a viable and recommended option for patients with low-risk and very low–risk prostate
cancer to avoid overtreatment,53,54 and active surveillance is now considered the preferred option
by multiple professional organizations.55 There can be significant cost savings for patients
undergoing active surveillance compared with up-front radical prostatectomy, potentially
representing a 43% to 79% cost savings.56 Studies have reported that campaigns to increase the use
of active surveillance have been largely successful,57,58 which is consistent with our detected
absolute increases of 13.5% in expansion states and 8.6% in nonexpansions states. However, many
studies have found that active surveillance is overall still underused, and its utilization is variable
among different practices and regions throughout the US.59,60 To our knowledge, our study is the
first to show an increase in use of active surveillance associated specifically with Medicaid expansion.
In contrast to the shift in stage at detection we observed in prostate cancer, the association
between Medicaid expansion and the observed shift in stage at detection for kidney cancer cannot
be explained by an increase in screening. There is no effective screening test for kidney cancer.
However, incidental diagnoses make up a significant and increasing portion of kidney cancer
diagnoses, and this may offer an explanation for the association between Medicaid expansion and
earlier-stage diagnosis of kidney cancer. Researchers have postulated that increased use of health
care services, particularly chest and abdominal imaging, was associated with the large increase in
incidence as well as a shift toward earlier-stage detection of kidney cancer observed in the 1990s and
early 2000s.61-65 In the years surrounding Medicaid expansion, the incidence of kidney cancer in the
US was relatively unchanged. However, studies have shown that the Medicaid expansion was
associated with increased preventive care visits66 and increased outpatient visits.67 Thus, there is a
similar potential explanation wherein the increased access to care and resources afforded by
Medicaid expansion may lead to increased incidental diagnosis at early stages when kidney cancer is
still asymptomatic. Unlike in prostate cancer, our data do not detect a corresponding shift toward
active surveillance, although they do indicate that active surveillance for kidney cancer increased in
expansion states by 0.7% and in nonexpansion states by 1.1%.

Figure 2. Trend of Patients With Low-Risk Prostate Cancer Patients Receiving Active Surveillance for All-Income and Low-Income Populations
A Proportion of low-risk or very low-risk prostate cancers receiving active
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Limitations
This study has some limitations. One potential limitation of this study is the geographic variability in
the proportion of cancer cases captured in the NCDB.66 Furthermore, Commission on Cancer–
accredited hospitals are more likely to be larger, academic, urban facilities that offer more cancerrelated services, such as screening, chemotherapy, and radiation.68 However, previous analyses,
such as a 2018 study by Eguia et al,27 have reported that most demographic and clinical
characteristics are remarkably similar between the NCDB and the population-based Surveillance,
Epidemiology, and End Results database. Another limitation is that our low-income population was
only able to be defined with zip code–level median income owing to lack of individual income
information. Additionally, while our study represents the most recently available data, several
additional states have expanded Medicaid coverage since 2016, and these ongoing expansions
highlight the need for continued research to include these states as well as to assess outcomes that
may require more than 3 years to reflect outcomes associated with Medicaid expansion.

Conclusions
This case-control study found that Medicaid expansion was associated not only with reductions in
uninsured status, but also with shifts toward earlier stages at diagnosis among kidney and prostate
cancers and higher rates of active surveillance among patients with low-risk prostate cancer. All these
outcomes were larger in magnitude in patients residing in low-income areas. This finding has
potential implications in that it shows expanded insurance may have positive impact on practice
patterns in cancer management, particularly in reducing inequity.
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